Aethlon Medical, Inc. (AEMD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -7 | -7 | ||||||
| Net profit | $m | -6 | -8 | -10 | -12 | -12 | -13 | -7 | -7 |
| EPS reported | $ | -10.61 | -11.70 | ||||||
| Operating cashflow per share | $ | -10.40 | -4,944 | ||||||
| Capex per share | $ | 0.01 | 23.79 | ||||||
| FCF per share | $ | -10.40 | -4,967 | ||||||
| Free cash flow | $m | -7,002,096 | -1,911 | ||||||
| Net debt | $m | -5 | -260 | ||||||
| Book value equity | $m | 5 | 5 | ||||||
| Book value per share | $ | 7.25 | 13.52 | ||||||
| Number of shares | m | 0.67 | 0.38 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.51 | 4.30 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -0.00 | -0.01 | ||||||
| EV/EBITDA LTM | x | -0.39 | -2.68 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -97.04% | -9.91% | ||||||
| FCF Yield | % | -95016466.9% | -8554.4% | ||||||
| Quality | |||||||||
| ROE | % | -146.36% | -123.09% | ||||||
| ROIC | % | -1.40% | -1.27% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -20,795,134.21 | -5,198.41 | ||||||
| Net Debt/EBITDA | x | 0.69 | 0.70 | ||||||
| EBIT/Net interest | x | -507.49 | -492.66 | ||||||
| Net debt/market cap | % | 0.00% | +11.74% | ||||||
| Net debt/Equity | x | -1.03 | -49.93 | ||||||
| Gross debt/equity | x | 0.07 | 0.07 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free